Previous 10 | Next 10 |
Initiating ReMEDy2 – Pivotal Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical Company focused on developing novel treatments for neurological disorders and kidney diseas...
DiaMedica Therapeutics Inc. (DMAC) Q1 2021 Earnings Conference Call May 6, 2021 8:00 AM ET Company Participants Rick Pauls - President & Chief Executive Officer Scott Kellen - Chief Financial Officer Harry Alcorn - Chief Medical Officer Conference Call Participants Alexander Nowak - Craig...
DiaMedica Therapeutics (DMAC): Q1 GAAP EPS of -$0.19.Cash, cash equivalents and marketable securities of $23.4MPress Release For further details see: DiaMedica Therapeutics reports Q1 results
Investigational New Drug (IND) Application Submitted for Phase 2/3 AIS Study Plan to Initiate Phase 2/3 AIS Trial in Summer 2021 REDUX Phase 2 Diabetic Kidney Disease Cohort Readout Expected in Q2 2021 Cash Runway Through Mid-2022 ...
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that its first quarter 2021 financial results will be released after the markets close on Wednesd...
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that the Rick Pauls, President and CEO, will deliver a corporate presentation at B. Riley’...
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that the Company will be presenting two abstracts at the National Kidney Foundation (NKF) 2021 Sp...
DiaMedica Therapeutics Inc. (DMAC) Q4 2020 Results Earnings Conference Call March 11, 2021, 08:00 AM ET Company Participants Rick Pauls - President & CEO Scott Kellen - CFO Harry Alcorn - Chief Medical Officer Conference Call Participants Alex Nowak - Craig-Hallum Etzer Darout - Guggenhei...
DiaMedica Therapeutics (DMAC): FY GAAP EPS of -$0.78 misses by $0.06.The Company had cash, cash equivalents and marketable securities of $27.5 million, current liabilities of $2.0 million and working capital of $25.9 million as of December 31, 2020.Press Release For further details see: ...
Productive Type B Pre-IND Meeting with FDA Provides Clarity for Planned Stroke Study Program On Track to Initiate Phase 2/3 AIS Trial in Summer 2021 REDUX Phase 2 Diabetic Kidney Disease Cohort Readout Expected in Q2 2021 ReMEDy Phase 2 AIS Stud...
News, Short Squeeze, Breakout and More Instantly...
DiaMedica Therapeutics Inc. Company Name:
DMAC Stock Symbol:
NASDAQ Market:
DiaMedica Therapeutics Inc. Website:
Company to Host Preeclampsia Key Opinion Leader Event July 29, 2024 at 10 AM Eastern / 9 AM Central White Paper: The Potential of DM199 to Treat Preeclampsia DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel trea...
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic disease, today announced the closing of its previously announced $11.8 million private placement to accredited investors. The Company sold approximatel...
A look at the top 10 most actives in the United States Faraday Future Intelligent Electric Inc. (FFIE) rose 73.0% to $0.4585 on volume of 640,087,036 shares Ocean Power Technologies Inc. (OPTT) rose 34.9% to $0.1812 on volume of 396,326,565 shares NVIDIA Corporation (NVDA) rose 0.2% to $1...